Skip to main content
Signal8
Launch Terminal

Vogenx, Inc. (VOGX)

Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Vogenx Inc. logo

Vogenx Inc.

NASDAQ:VOGXHealthcare
-0.63%$17.34
AH Close$17.34+0.00%vs close
Mkt Cap$257.59M
Float9.47M
O/S14.86M
Inst Own-
SI0.4%
Dilution
Vogenx Inc. logoNASDAQ:VOGX$17.34-0.63%
FormDescription
8-K
5.02,7.01,9.01
2
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
8-K
5.02,7.01,9.01
10-Q
Quarterly Report
6
13G
Beneficial Ownership Report
8-K
8.01
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.03,9.01
S-8
SEC Filing
424B4
Prospectus
EFFECT
Notice of Effectiveness
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 34

    Vogenx, Inc. (VOGX) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8